The Potential of HER2-, HER3-, and TROP2-Targeted Therapies to Address Unmet Needs in Advanced NSCLC

Are You Prepared for the New Wave of ADCs in NSCLC? Targeting HER2, HER3, TROP2, and OthersПодробнее

HER2 Targeted Therapy for Treatment of NSCLCПодробнее

HER2 and HER3 Alterations as Therapeutic Targets of Increasing Significance in Solid TumorsПодробнее

Addressing Key Targets in Advanced NSCLC: HER2-, HER3-, and TROP2-Targeted TherapiesПодробнее

Moving Toward Expanded Precision Treatment of HER2- or HER3-Driven Breast, GI, Lung & Other CancersПодробнее

GRACEcast - Treatment options for patients with advanced NSCLC and a HER2- ERBB2 mutationПодробнее

Understanding HER2 Alterations in Advanced Non-Squamous NSCLCПодробнее

Why do certain cancers seem resistant to treatment?Подробнее

Unlocking the Potential of TROP2-Targeted Therapy: Breakthroughs in NSCLC Therapeutic ApproachesПодробнее

The future of NSCLC treatmentПодробнее

Strategies to Target HER2 in Lung CancerПодробнее

Taking Aim With the Next Wave of Antibody–Drug Conjugates in NSCLC to Address Unmet NeedsПодробнее

HER2 Mutation Positive NSCLCПодробнее

Novel targeted therapies for NSCLC: Exploring HER2 dysregulationПодробнее

Dr. Bunn on Targeting HER3 in NSCLCПодробнее

Ep 4: Oncology Morning Commute: Targeting HER2, HER3, and TROP2 in NSCLCПодробнее

Drs. Johnson, Levy, & Yu discuss the latest Lung Cancer updates from #WCLC21: https://bit.ly/3gOriYoПодробнее

Dr. Pennell on the Evolution of Targeting HER2 in Lung CancerПодробнее

Targeted Therapy for HER2 & HER3-Positive Breast Cancer: Navigating the Evolving Treatment LandscapeПодробнее